| Agile Therapeutics is a women's healthcare company. Co.'s primary product candidate, Twirla, is a once-weekly prescription combination hormonal contraceptive patch. It delivers a dose of estrogen that is consistent with commonly prescribed combined hormonal contraceptives. Co.'s pipeline consists of two classes of product candidates: Co.'s potential product pipeline consists of two types of product candidates: a progestin-only contraceptive patch and potential Twirla line extensions. These potential product candidates are designed to address market needs and provide additional non-daily contraceptive options. Including AG200-15 Extended Regimen, AG200-SmP, and AG200-15 ER SmP. We show 33 historical shares outstanding datapoints in our AGRX shares outstanding history coverage, used to compute AGRX market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AGRX market cap history over the course of time is important for investors
interested in comparing AGRX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AGRX versus a peer is one thing; comparing
AGRX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AGRX can fluctuate over the course of history.
With this page we aim to empower investors researching AGRX by allowing them to research the AGRX market cap history.